Our focus areas
Biotech and pharmaceuticals
In life sciences, we have a strong track record in domestic and cross-border mergers and acquisitions, helping our clients to monetise their assets through creative partnering with early-stage entrepreneurial and established companies, and by providing IP and tax advice.
Digital health
Our specialist healthcare technology practice advises the companies and investors that are transforming the way therapies and patient services are delivered.
Healthcare
In health and social care, we advise on everything from the building and operating of hospitals and care homes to the provision of new methods of diagnosis and treatment.
Experience
Bone Therapeutics
Advised Bone Therapeutics, addressing high unmet medical needs in orthopaedics and bone diseases, on its €16 million loan financing from the European Investment Bank to support and prepare their lead asset, enhanced viscosupplement JTA-004, for future regulatory approval and commercialisation. Read more here >
NeRRe Therapeutics
Advised NeRRe Therapeutics on its £20 million Series B2 financing round. The financing involved a syndicate of leading transatlantic life sciences investors led by new investor Columbus Venture Partners and existing investors Advent Life Sciences, Fountain Healthcare Partners, Forbion Capital Partners and OrbiMed. Read more here >
Grifols
Advised global healthcare leader, Grifols on a ~USD 1 billion strategic investment from Singapore’s sovereign wealth fund. Read more here >
firstminute capital
Osborne Clarke advises firstminute capital on investment in Vantis, read more
Amphista Therapeutics
Advised Amphista Therapeutics, a leader in next generation targeted protein degradation (TPD) approaches, on its $53 million (£38 million) Series B financing round. Read more.
Grifols
Advised Grifols on its strategic alliance and investment in Shanghai RAAS.
LDC
Advised long-standing client LDC together with the management team on the sale of Penn Pharma in a transaction worth £127m.
Univercells
Advised on a series A investment in Belgian biotech company Univercells.
Telefonica Alpha
Advised Telefonica Alpha (Barcelona) on a software service and the applicability of both healthcare and medical device regulation.
UK telco
Advised a UK telco on regulatory compliance for a range of proposed 'mhealth' services, including whether the services were healthcare services and/or used medical devices.
Healthcare provider
Advised a digital primary care healthcare provider on EU and UK health and data regulations, preparing global contracting documentation and insurance advice.
Intrapharm Laboratories Ltd
Advised Intrapharm Laboratories Ltd management team and all of its shareholders on the disposal of the company to German pharmaceutical company RIEMSER Pharma GmbH.
Drug discovery company
Advised the shareholders of a privately held drug discovery company on its acquisition by C4X Discovery Holdings plc in exchange for shares in C4X.
Roche Diagnostics GmbH
Advised Roche Diagnostics GmbH on the revision of their privacy policy and end-user licence agreements.
Roche Diagnostics GmbH
Advised Roche Diagnostics GmbH on a cloud-based solution for securely hosting critical medical data in compliance with data protection laws in over 30 countries.
Imperial Innovations Group plc
Advised Imperial Innovations Group plc and SV Life Sciences on a £19 million series A investment in Kesios Therapeutics.
First Water
Advised the shareholders of First Water on its acquisition by Scapa Group for consideration of up to £15.3m payable depending on performance in 2016, 2017 and 2018.
Sirigen Group Ltd
Advised medical technology Sirigen Group Ltd on its acquisition by Becton, Dickinson and Company, a leading global medical technology company, for an undisclosed sum.
Takeda Ventures
Advised Takeda Ventures, Inc and Takeda Pharmaceuticals on the investment and formation of a drug discovery collaboration with Heptares Therapeutics Ltd.
Fact #20
We advised Grifols on its €5bn acquisition of US company Talecris
Life Sciences and HealthcareInsights
-
Dealing with healthcare data: an overview of the key European markets
Handling health data can be a challenge. Depending on where you are based, you'll need to have a strong grasp of the national landscape in order to benefit from the…
-
Hemp tea – the fine line between food and narcotics
The first article from our series "Cannabis - the 'green gold' from a legal perspective"
-
HMRC publishes call for evidence on simplifying the VAT land exemption
Proposals for simplification could mean a radical overhaul of the VAT exemption for land and property and those impacted by the changes should engage with HMRC.
Connect with one of our experts
